Q32 Bio Inc.
QTTB · XNASCIK 1661998fmd_0PRTAS2V6VZ726TB0S0YDB76T9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 39 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 5 | 2 | 3 | 34 | 3 | (7) | 0 | 54 |
| Net interest income | – | – | – | – | – | – | 1 | 3 | 1 |
| Research and development | 21 | 48 | 89 | 100 | 93 | 98 | 32 | 48 | 19 |
| Total operating expenses | 30 | 65 | 112 | 133 | 130 | 136 | 42 | 66 | 37 |
| Operating income | (30) | (60) | (110) | (130) | (96) | (133) | (48) | (66) | 17 |
| Interest expense | – | – | – | – | – | – | 2 | – | – |
| Other non-operating income (expense) | (0) | 4 | 6 | 2 | 0 | 134 | (5) | 20 | 13 |
| Income before taxes | – | – | – | – | (96) | 1 | (53) | (46) | 30 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (96) | 0 | (54) | (46) | 30 |
| Net income | (30) | (56) | (104) | (129) | (96) | (5) | (54) | (48) | 30 |
| Net income to common shareholders | – | – | – | – | – | – | (0) | (0) | 0 |